Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMB-01 in Patients With Advanced/Metastatic Solid Tumors
NCT03797391Phase 2Recruiting
- Sponsor
- EpimAb Biotherapeutics
- Start
- Dec 2018
- Primary completion
- Mar 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of emb-01 in solid tumor and non-small cell lung cancer (NSCLC), sponsored by EpimAb Biotherapeutics. Primary endpoints: Maximum Tolerated Dose, Adverse Events and Serious Adverse Events and 1 more. Started Dec 2018; status: recruiting.
02
Drugs
emb-01
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03797391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03797391.